Development of a versatile enrichment analysis tool reveals associations between the maternal brain and mental health disorders, including autism

Brian E Eisinger¹*, Michael C Saul¹, Terri M Driessen¹ and Stephen C Gammie¹,²

Abstract

Background: A recent study of lateral septum (LS) suggested a large number of autism-related genes with altered expression in the postpartum state. However, formally testing the findings for enrichment of autism-associated genes proved to be problematic with existing software. Many gene-disease association databases have been curated which are not currently incorporated in popular, full-featured enrichment tools, and the use of custom gene lists in these programs can be difficult to perform and interpret. As a simple alternative, we have developed the Modular Single-set Enrichment Test (MSET), a minimal tool that enables one to easily evaluate expression data for enrichment of any conceivable gene list of interest.

Results: The MSET approach was validated by testing several publicly available expression data sets for expected enrichment in areas of autism, attention deficit hyperactivity disorder (ADHD), and arthritis. Using nine independent, unique autism gene lists extracted from association databases and two recent publications, a striking consensus of enrichment was detected within gene expression changes in LS of postpartum mice. A network of 160 autism-related genes was identified, representing developmental processes such as synaptic plasticity, neuronal morphogenesis, and differentiation. Additionally, maternal LS displayed enrichment for genes associated with bipolar disorder, schizophrenia, ADHD, and depression.

Conclusions: The transition to motherhood includes the most fundamental social bonding event in mammals and features naturally occurring changes in sociability. Some individuals with autism, schizophrenia, or other mental health disorders exhibit impaired social traits. Genes involved in these deficits may also contribute to elevated sociability in the maternal brain. To date, this is the first study to show a significant, quantitative link between the maternal brain and mental health disorders using large scale gene expression data. Thus, the postpartum brain may provide a novel and promising platform for understanding the complex genetics of improved sociability that may have direct relevance for multiple psychiatric illnesses. This study also provides an important new tool that fills a critical analysis gap and makes evaluation of enrichment using any database of interest possible with an emphasis on ease of use and methodological transparency.

Keywords: Autism, Schizophrenia, Bipolar disorder, Depression, ADHD, Mental health, Enrichment analysis, Maternal brain, Lateral septum

* Correspondence: beeisinger@wisc.edu
¹Department of Zoology, University of Wisconsin-Madison, Madison, Wisconsin, USA
© 2013 Eisinger et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Large scale, genome wide expression studies (such as exon microarrays, promoter microarrays, ChIP-on-CHIPS, and next gen sequencing) have allowed researchers to move from traditional approaches that focus on analyzing one or a few genes to new methods that generate high volumes of simultaneously collected expression data for tens of thousands of genes. This represents a powerful opportunity to identify alterations in large scale biological processes relevant to the study being performed, but it has also created a highly complex data environment with a unique set of challenges. Over the last decade, new software for analyzing enrichment of functionally related gene groups in large scale gene expression data has been developed and implemented successfully. There is an abundance of programs currently available that perform enrichment analyses in a variety of ways, each with its own advantages, disadvantages, and suitable applications [1-6].

Our laboratory recently carried out microarray experiments to explore gene expression changes in the lateral septum (LS) of outbred mice associated with the transition from a virgin to lactating, maternal state. The LS is part of an interconnected network of brain regions known to be critically important in social and maternal behavior [7,8]. Several enrichment analyses were performed, including the Broad Institute’s Gene Set Enrichment Analysis (GSEA) and the NIH’s Database for Annotation, Visualization and Integrated Discovery (DAVID) [1,3,9,10]. These programs proved to be fruitful in profiling large scale alterations in functionally related networks of genes in the postpartum LS, and enrichment was discovered for pathways related to ion channel activity, developmental processes, cyclic nucleotide metabolism, nucleosome components, and the Ras superfamily of small GTPases [11].

We began to notice that numerous genes among the most significant expression results in maternal LS had strong links to autism. This was intriguing because both autism and maternity involve behavioral and emotional alterations. Autism is a pervasive class of spectrum disorders typically characterized by deficits in social interaction, impaired communication abilities, and patterns of repetitive behavior [12,13]. Autistic individuals can have difficulty empathizing with others, developing spoken language, and maintaining relationships [14,15]. In comparison, the transition from a virgin to postpartum state represents a profound transformation in which an animal that was previously concerned mostly with its own survival develops heightened aspects of sociability and becomes critically focused on the wellbeing of its offspring [16]. Because the establishment of the maternal phenotype is a natural process, the postpartum, outbred mouse provides a useful model for exploring the genetics of social behavior and its dysregulation [17]. Oxytocin and vasopressin signaling in rodent maternal care has recently been investigated for its translational relevance to autism spectrum disorders in humans [18-22]. Moving from a single molecule focus to large scale genetic comparisons between the maternal brain and autism may provide broader insight to the neurological basis of sociability and contribute to our understanding of mental health disorders.

We recognized that it would be valuable to formally test for enrichment of autism-related genes in the maternal LS, but we quickly encountered several difficulties. Most available enrichment analysis tools operate solely on functional and pathway association databases, such as Gene Ontology (GO) terms or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, and do not include curated groups of disease-linked genes [1]. The handful of programs that do support disease ontology make use of only few predominant disease databases, such as the Online Mendelian Inheritance in Man (OMIM) and the Genetic Association Database (GAD) [23-25]. These databases are detailed and comprehensive, but because enrichment analysis is critically sensitive to the gene lists used as input, it is detrimental to be restricted to a single source of disease associations. There is a vibrant landscape of researchers and organizations that build and maintain numerous genetic disease association databases, but these resources are not linked to any formal means of enrichment analysis (Additional file 1: Table S1) [26-29]. In addition to comprehensive collections of gene-disease associations that encompass many diseases, it is not uncommon for a high profile disorder to engender a community of foundations, initiatives, and projects dedicated to furthering genetic research for that disease alone. For autism in particular, such notable groups include AutismKB by Peking University’s Center for Bioinformatics [30], AutDB by the nonprofit organization Mindspec [31], and the Autism Genetic Database (AGD) [32]. Furthermore, ongoing research continuously generates new sets of candidate autism genes through a variety of novel techniques. For example, one recent publication used a novel Genome-wide Association Study method that reduces statistical noise and minimizes false positives to build a list of autism candidate genes [33], while another group used a functional profile of 84 autism-linked genes to screen the human genome for a larger set of predictive autism susceptibility genes [34].

To make use of this deep and varied field of autism genetics in enrichment analysis, it was clear that researchers must be allowed to create and use custom gene lists in a statistically robust hypothesis testing method. While some popular enrichment packages permit the inclusion of user-generated gene lists, the practicality of this feature often suffers from overly complex,
opaque computations and internal significance corrections, a loss of large scale expression data fidelity through forced species-to-species conversions, and a heavy reliance on gene ranking methods and myriad configuration options that can easily lead to vastly different results that may be spurious or open to misinterpretation. As a simple alternative that focuses on the use of custom gene lists, we developed the Modular Single-set Enrichment Test (MSET) – a minimal randomization script that allows researchers to create and utilize any list of disease-associated genes as modules for enrichment testing and gene identification. 

MSET is designed to be accessible and easy for researchers of any background to use; it runs in R (free to download), requires only a single command line to execute, and subsequently interacts with the user via a simple window and text prompt interface. The lightweight architecture of the program confers independence from platform specific or species specific annotation systems and introduces minimal additional handling of expression data. Such an approach trades the exploratory aspect of full-featured enrichment software that searches for and scores enrichment across numerous biological pathways for a more focused hypothesis testing analysis for enrichment in diseases of interest. This allows investigators to use the most current database for a given disorder, customize their own, or repeat the analysis using numerous databases to generate a comprehensive meta-analysis and obtain high confidence in their results. Another important aspect of MSET is that it quickly highlights genes of interest that can be examined in follow up studies. As a result of its versatility, modular power, and ease of use, MSET represents an improvement over existing tools for performing enrichment analysis with independently assembled disease-associated gene sets.

Using the MSET approach, we discovered a striking consensus of enrichment for expression changes of autism-related genes across nine independent databases in the maternal LS compared to virgin. We found additional evidence of enrichment in the maternal LS for several other mental health diseases, including bipolar disorder, depression, and schizophrenia. This article will serve to present the biological findings from our data, as well as to introduce and demonstrate the novel enrichment tool used to generate them.

**Implementation**

MSET is a script written in R that calls upon text files saved within the same folder as the script itself. Outlined simply, the MSET script is a randomization test that calculates the probability of randomly generating a set of microarray results that includes as many disease-associated genes as does a set of results from an actual experiment. It requires two input files: 1) a gene list of interest from a disease association database (autism-associated genes, schizophrenia-associated genes, etc.) for which enrichment will be evaluated, and 2) a full list of all microarray gene results ordered by significance. After choosing a threshold for how many of the top genes will be examined for enrichment, MSET saves them as a list of significant expression results. This list is separate from the full microarray results, which is also known as the microarray background. MSET then generates a specified number of simulated results by sampling randomly and without replacement from the microarray background. It counts the number of genes in each set of simulated results that appear in the gene list of interest (matches to database), and the p-value is calculated as the proportion of simulated results which contained at least as many matches to database as the actual significant expression results.

MSET analysis is performed at the gene level, but microarray platforms can include probes that target intergenic areas and lack a gene ID annotation. Prior to permutation testing, these non-annotated reads are removed from the significant microarray results. Because some genes in microarrays may be assigned multiple probe sets, duplicate gene IDs are also removed from the top selected significant results list, such that each gene is represented only once. The same treatments are applied to the gene list of interest database to ensure completeness and uniqueness. For the microarray background, targets without annotations to genes are removed, but duplicate targets for a single gene are retained. This is part of a strategy to preserve true-to-platform probabilities when sampling targets from the background to build simulated results.

After the user specifies the number of simulated results to be generated from the microarray background (e.g., 10,000), the script begins sampling without replacement. For each simulated set of results, MSET actually builds a list that is twice the length of the true significant results, removes duplicate genes from it, and then discards the excess genes such that the simulated results list is then the same length as the actual results. In this way, genes that are represented by many probes have a greater chance to be included in the simulated results, corresponding to their “weight” in the microarray platform. This allows for simulated results that are true to the particular microarray platform.

MSET output consists of two elements; a graph of the probability distribution of matches to database in simulated results, and a text readout with a variety of information about the input gene lists, the simulated results, and enrichment p-value. It also displays the individual disease-associated genes from the database of interest that appeared in the actual microarray results.
All expression data used in this study were taken from published microarray studies that have been uploaded to NCBI's Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) or an institutional website. Details of experimental design are provided in the original publications. Postpartum LS expression data were prepared in our laboratory with the Probe Logarithmic Intensity Error (PLIER) algorithm. For data accessed via the GEO, gene expression changes between experimental groups were ranked by the built-in GEO2R tool. While a researcher can decide which probe set algorithm is optimal for their particular microarray experiment, differences in the current study are small enough that both methods yield approximately similarly ordered results.

The data sets supporting the results of this article are available via NCBI's Gene Expression Omnibus (GEO) with the following links and accession numbers:

http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27492
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43627
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22371
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33619

Results

Nine independent online databases were selected as sources for autism-associated genes (Additional file 1: Table S1). Of these, four are general disease association databases, three are autism-specific aggregations, and two are recent publications that generated candidate autism gene lists. The autism gene lists extracted from the selected databases exhibited varying sizes and degrees of similarity as assessed by pairwise comparisons, but are generally non-redundant. Figure 1 illustrates the relatedness of the autism databases and shows how they fit into the modular workflow of the enrichment analysis.

A set of 809 genes displayed significant changes in expression in the postpartum LS relative to virgin (FDR-adjusted p < 0.25) as measured by microarray analysis. Within these results, enrichment for all nine autism gene lists was detected (Figure 1, p < 0.05). Collectively, 160 autism-associated genes were identified in the significant maternal LS expression results (Additional file 2: Table S2). To highlight the genes in this group that have the most evidence for an association to autism, 36 differentially expressed genes in the postpartum LS which appeared in three or more autism databases are shown in Table 1. A functional profile of all 160 autism-linked genes in the postpartum LS results generated by NIH's DAVID functional annotation clustering tool revealed striking themes of differentiation/development, synaptic plasticity, and neuronal signaling (Table 2). Using gene lists extracted from the general disease association databases, enrichment was additionally discovered in the maternal LS for genes related to bipolar disorder, schizophrenia, ADHD, and depression. This is shown in Figure 2, which is a comprehensive heat map that summarizes enrichment results for all data sets analyzed in this study.

As a demonstration of MSET's applicability, enrichment of autism gene lists was evaluated in a set of microarray results from the developing neocortex of T-box brain gene 1 (Tbr1) null mice, a putative model for autism genetics. In the 809 most significant results, these expression data exhibited compelling enrichment in seven out of the nine autism gene lists (P < 0.05), with subtler enrichment in two gene lists that bordered on or failed to reach significance (Figure 3). In contrast to the maternal LS results, the Tbr1 data showed little to no enrichment in genes associated with other mental health disorders (Figure 2).

Furthermore, enrichment analysis for the full complement of mental health disorders was conducted within a set of 809 significantly altered genes in microarray results from mice treated with methylphenidate, a common treatment for ADHD. These expression data exhibited some enrichment for autism gene lists (two out of nine, p < 0.05), but notably showed high enrichment specifically for ADHD gene lists (Figure 2).

As a test for specificity of MSET analysis, enrichment for autism and arthritis-associated gene lists was compared within two sets of expression data; the 809 significant maternal LS microarray results and 809 microarray results from a serum induced murine arthritis model. Enrichment of arthritis-associated genes was detected in the arthritis model expression data, but not in the maternal LS results (p < 0.05). Additionally, enrichment of autism gene lists was not detected within the arthritis model results (Figure 4). The arthritis model results failed to show enrichment for any of the mental health disorders (Figure 2).

Discussion

In this study, we have introduced the Modular Single-set Enrichment Test (MSET), a newly developed tool designed for assessing enrichment of disease/disorder-associated gene sets within microarray results. In addition to demonstrating the capabilities and limitations of this novel software, we used it to discover a strong link between the maternal brain and autism, as well as several other mental health disorders. We subsequently identified a network of candidate genes that may influence sociability in mothers and revealed the functional character of this network to be primarily related to developmental and neuronal signaling processes.

Enrichment in postpartum LS for autism, and other mental health disorders

The compelling enrichment of autism-associated genes found in expression changes of the postpartum LS...
Figure 1 (See legend on next page.)
Figure 1 Autism database comparison, modular workflow of MSET analysis, and autism enrichment evaluation of postpartum LS expression results. A) Pairwise comparison of redundancy in gene lists extracted from autism databases, calculated as the proportion of the smaller list that is identical to the larger list. Dark green corresponds to the highest possible redundancy (1), and red represents the least redundancy (0). B) Schematic view of modules that can be combined in MSET analysis. Enrichment of any gene database in the left hand column can be assessed within any set of expression data from the right hand column. The grey path connecting modules highlights the specific combination whose output is shown in the enlarged window in panel C. C) Output of MSET analysis for nine autism databases within postpartum LS expression results. The first window displays enrichment of Autism Genetic Database (AGD) genes within postpartum LS expression data, and is enlarged to include explanatory labels that highlight the important features of the graphical output. Y-axis represents the probability of X matches to database found in a randomly generated set of simulated results from the microarray background. The blue arrow shows how many matches were found in the actual significant postpartum LS expression changes and where that number falls on the probability density distribution. The enrichment p-value is derived from the number of simulated results that contained at least as many matches to database as the actual results. The following windows show MSET enrichment analyses for the other eight autism databases within postpartum LS expression data.

(Figure 1) is, to our knowledge, the first demonstration of a genetic link between the maternal brain and pathways involved in autism. The discovery of enrichment in postpartum LS for several mood/social disorders (Figure 2) suggests that the phenotypic consequence of LS gene changes in the transition to motherhood possesses a significant behavioral and emotional component. Because the mother-infant relationship is the first and foremost social bond formed in mammals, it has been suggested that the genetic and neural networks underlying sociability in this ancestral event might serve as an evolutionary template from which sociability in other contexts is derived [35]. Our data indirectly support this concept on a large-scale genetic level. While autism rates are higher in males [36], it could be the conserved use of the same core genes for sociability that provides the connection between autism and the maternal brain. Furthermore, the severity of autism symptoms is often described as spectral, rather than binary. It is therefore plausible that subtle dysregulation of genes which are naturally modulated in the control of sociability, such as in the transition to motherhood, would more likely contribute to this observed phenomenon than would rarer gain-of-function or loss-of-function mutations.

Table 1 includes several autism-linked genes that were identified in our original microarray analysis as particularly interesting based on their biological function and relevance to emotional state and behavior. These include the GABA_A receptor subunits α4 and δ, four potassium channel subunits (Kcnndl2, Kcnndl3, Kcnhd7, and Kcnhd4), dopamine receptors Drd1a and Drd2, the kappa opioid receptor Oprk1, fatty acid binding protein 7 (Fabp7), and suppressor of cytokine signaling 2 (Socs2). The biology of these genes is discussed in greater detail in our original report [11].

NIH DAVID’s functional annotation clustering tool was used to generate a functional profile of the 160 autism-associated genes found to be differentially expressed in the postpartum LS (Table 2). The most highly enriched pathways were primarily developmental, involving processes such as synaptic plasticity, neuronal morphogenesis/differentiation, and cell motility. Several clusters related to synaptic transmission also showed high levels of enrichment. Because these biological processes have now been implicated in both autism and the maternal LS, it is likely that aspects of sociability modulated in both phenomena are influenced by structural changes in the brain, including...
Table 1 Genes with strong links to autism found in significant postpartum LS expression changes

| Gene symbol | Gene name                                      | Autism databases |
|-------------|------------------------------------------------|------------------|
| Foxp2       | Forkhead box P2                                | 7                |
| Sez62       | Seizure related 6 homolog like 2               | 7                |
| Laminb1     | Laminin B1                                     | 7                |
| Slc1a1      | Solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 | 7 |
| Adora2a     | Adenosine A2a receptor                          | 6                |
| Gabra4      | Gamma-aminobutyric acid (GABA) A receptor, subunit alpha 4 | 5 |
| Hras1       | Harvey rat sarcoma virus oncogene 1            | 5                |
| Atrx        | Axyl hydrocarbon receptor nuclear translocator 2 | 5                |
| Lrfn5       | Leucine rich repeat and fibronectin type III domain containing 5 | 4 |
| Scn1a       | Sodium channel, voltage-gated, type I, alpha   | 4                |
| Drd2        | Dopamine receptor D2                            | 4                |
| Nostrin     | Nitric oxide synthase trafficker               | 4                |
| Npy         | Neuropeptide Y                                 | 4                |
| Snrpn       | Small nuclear ribonucleoprotein N              | 4                |
| Fabp5       | Fatty acid binding protein 5, epidermal        | 4                |
| Pcdh10      | Protocadherin 10                               | 4                |
| Kcdn2       | Potassium voltage-gated channel, Shal-related family, member 2 | 3 |
| Upp2        | Uridine phosphorylase 2                        | 3                |
| Rbofox1     | RNA binding protein, fox-1 homolog (C. elegans) | 3                |
| Adra2a      | Adrenergic receptor, alpha 2a                  | 3                |
| Cadps2      | Ca2+ -dependent activator protein for secretion 2 | 3                |
| Camk2b      | Calcium/calmodulin-dependent protein kinase II, beta | 3 |
| Csmd3       | CUB and Sushi multiple domains                 | 3                |
| Dro7       | Dopamine receptor D1A                          | 3                |
| Fabp7       | Fatty acid binding protein 7, brain            | 3                |
| Fox01       | Forkhead box O1                                | 3                |
| Hcrt1       | Hypocretin (orexin) receptor                   | 3                |
| Htr5a       | 5-hydroxytryptamine (serotonin) receptor 5A    | 3                |
| Mchr1       | Melanin-concentrating hormone receptor 1       | 3                |
| Nr2e1       | Nuclear receptor subfamily 2, group E, member 1 | 3               |
| Oprk1       | Opioid receptor, kappa 1                       | 3                |
| Pdeo4b      | Phosphodiesterase 4B, cAMP specific            | 3                |
| Ppilig1b     | Protein phosphatase 1, regulatory (inhibitor) subunit 1B | 3 |
| Rarb        | Retinoic acid receptor, beta                   | 3                |
| Robo2       | Roundabout homolog 2 (Drosophila)             | 3                |
| Tac1        | Tachykinin 1                                   | 3                |

All genes in Table 1 have expression changes with FDR-adjusted p-values less than 0.25. The farthest right hand column shows the number of autism databases in which the gene was featured, and represents a putative strength of evidence for a positive association to autism. Only genes that appeared in three or more lists are shown here. A full list of autism-associated genes from all databases found in postpartum LS expression changes is provided in Additional file 2: Table S2.
Table 2 NIH DAVID functional annotation clustering of autism-associated genes found to be significantly altered in postpartum LS

| Cluster                                           | Enrichment score | Genes                      |
|---------------------------------------------------|------------------|----------------------------|
| Synapse/Cell Junction                             | 7.69             | Cadps                      |
|                                                   |                  | Ctnnb1                     |
|                                                   |                  | Gabrd                      |
|                                                   |                  | Pclo                       |
|                                                   |                  | Syt6                       |
|                                                   |                  | Rasgrp2                    |
|                                                   |                  | Cplx2                      |
|                                                   |                  | Grik1                      |
|                                                   |                  | Scn1a                      |
|                                                   |                  | Snapin                     |
|                                                   |                  | Cpeb1                      |
|                                                   |                  | Grm3                       |
|                                                   |                  | Sv2c                       |
|                                                   |                  | Adora2a                    |
|                                                   |                  | Dlg1                       |
|                                                   |                  | Lrfn1                      |
|                                                   |                  | Synpr                      |
|                                                   |                  | Camk2a                     |
|                                                   |                  | Gabra4                     |
|                                                   |                  | Phactr1                    |
|                                                   |                  | Syt5                       |
| Regulation of synaptic plasticity/transmission    | 4                | Hras1                      |
|                                                   |                  | Drd1a                      |
|                                                   |                  | Adora2a                    |
|                                                   |                  | Grik1                      |
|                                                   |                  | Camk2a                     |
|                                                   |                  | Grm3                       |
|                                                   |                  | Cpeb1                      |
|                                                   |                  | Drd2                       |
| Neuron projection morphogenesis                   | 3.75             | Dscam                      |
|                                                   |                  | Adora2a                    |
|                                                   |                  | Gas7                       |
|                                                   |                  | Klf7                       |
|                                                   |                  | Baiap2                     |
|                                                   |                  | Nr2e1                      |
|                                                   |                  | Sh2b1                      |
|                                                   |                  | Ctnnb1                     |
|                                                   |                  | Phgdh                      |
|                                                   |                  | Slitrk1                    |
|                                                   |                  | Cxcr4                      |
|                                                   |                  | Actg1                      |
|                                                   |                  | Alcam                      |
|                                                   |                  | Drd2                       |
|                                                   |                  | Robo2                      |
| Cyclic nucleotide mediated signaling              | 3.35             | Htr5a                      |
|                                                   |                  | Pclo                       |
|                                                   |                  | Adora2a                    |
|                                                   |                  | Tshr                       |
|                                                   |                  | Drd2                       |
|                                                   |                  | Drd1a                      |
|                                                   |                  | Gna11                      |
| Cell morphogenesis/differentiation                | 2.73             | Dscam                      |
|                                                   |                  | Cxcr4                      |
|                                                   |                  | Klf7                       |
|                                                   |                  | Drd2                       |
|                                                   |                  | Slitrk1                    |
|                                                   |                  | Nr2e1                      |
|                                                   |                  | Alcam                      |
|                                                   |                  | Robo2                      |
|                                                   |                  | Ctnnb1                     |
| Neurogenesis/nervous system development           | 2.48             | Ascl1                      |
|                                                   |                  | Smo                        |
|                                                   |                  | Ctnnb1                     |
|                                                   |                  | Robo2                      |
|                                                   |                  | Drd2                       |
|                                                   |                  | Socs2                      |
|                                                   |                  | Mapt                       |
|                                                   |                  | Nr2e1                      |
| Regulation of glutamine/amine/GABA signaling      | 2.44             | Adora2a                    |
|                                                   |                  | Drd2                       |
|                                                   |                  | Drd1a                      |
|                                                   |                  | Grik1                      |
|                                                   |                  | Nhnt                       |
| Cell motility/migration                           | 2.4              | Flt1                       |
|                                                   |                  | Drd1a                      |
|                                                   |                  | Ascl1                      |
|                                                   |                  | Nr2e1                      |
|                                                   |                  | Cxcr4                      |
|                                                   |                  | PexSl                      |
|                                                   |                  | Cx3cl1                     |
|                                                   |                  | Smo                        |
|                                                   |                  | Drd2                       |

Enrichment scores were calculated for all 160 autism-associated genes found in significant postpartum LS results (FDR-adjusted p < 0.25, Additional file 2: Table 2) by NIH DAVID’s functional annotation clustering with “high” stringency setting selected.
To test for expected specificity of MSET analysis, we assessed enrichment for the full range of disease-associated gene sets within microarray expression data from a murine arthritis model study in which an arthritic state was induced via the transfer of serum from a knockout mouse into a wild type animal [58]. Complementary findings to the postpartum LS results were observed, in which the arthritis model data showed enrichment specifically for arthritis-associated gene sets, but not for autism (Figure 4) or any other mental health disorders (Figure 2). Collectively, these results demonstrate that the enrichment analysis performed in the present study is reliable and specific. Specificity may not be expected in every application, as different models and experimental treatments used in microarray studies can affect broad or unanticipated gene pathways.

**Figure 2** MSET enrichment summary heat map for numerous disease-associated gene lists within multiple sets of expression data. Gene lists representing each disease/disorder were extracted from databases shown in the far left column. Significance of enrichment p-values are mapped to a color spectrum as shown in the key (upper left). The four columns farthest to the right correspond to each set of expression data evaluated in this study.

| Database                  | Disease          | Expression data          | Postpartum LS | Tbr1 null | Methylphenidate treated | Arthritis model |
|---------------------------|------------------|--------------------------|---------------|-----------|-------------------------|-----------------|
| AGD                       | Autism           | 0.004                    | <0.001        | <0.001    | 0.381                   | 0.262           |
| AutDB                     |                  | <0.001                   | <0.001        | 0.002     |                         | 0.624           |
| AutismRB                  |                  | 0.037                    | <0.001        | 0.012     |                         | 0.256           |
| "Noise-reduction GWAS"    |                  | <0.001                   | 0.004         | 0.454     |                         | 0.929           |
| "Predictive gene map"     |                  | 0.007                    | 0.008         | 0.146     |                         | 0.455           |
| DISEASES database         |                  | <0.001                   | <0.001        | 0.352     |                         | 0.996           |
| GAD                       | Bipolar disorder | 0.078                    | 0.232         | 0.412     |                         | 0.518           |
| HuGE Phenopedia           |                  | <0.001                   | 0.365         | 0.089     |                         | 0.986           |
| Malacards                 |                  | <0.001                   | 0.542         | 0.139     |                         | 0.949           |
| DISEASES database         | Schizophrenia    | <0.001                   | 0.293         | 0.231     |                         | 0.994           |
| GAD                       |                  | <0.001                   | 0.121         | 0.176     |                         | 0.991           |
| HuGE Phenopedia           |                  | <0.001                   | 0.452         | 0.007     |                         | 0.998           |
| Malacards                 |                  | <0.001                   | 0.096         | 0.197     |                         | 0.808           |
| DISEASES database         | ADHD             | 0.030                    | 0.549         | 0.005     |                         | 0.744           |
| GAD                       |                  | <0.010                   | 0.414         | 0.058     |                         | 0.468           |
| HuGE Phenopedia           |                  | <0.001                   | 0.642         | 0.005     |                         | 0.988           |
| Malacards                 |                  | 0.002                    | 0.142         | 0.026     |                         | 0.783           |
| DISEASES database         | Depression       | 0.003                    | 0.812         | 0.817     |                         | 0.184           |
| GAD                       |                  | 0.021                    | 0.355         | 0.440     |                         | 0.619           |
| HuGE Phenopedia           |                  | <0.001                   | 0.041         | 0.314     |                         | 0.945           |
| Malacards                 |                  | <0.001                   | 0.215         | 0.837     |                         | 0.879           |
| DISEASES database         | Arthritis        | 0.451                    | <0.001        | 0.265     | <0.001                  |                 |
| GAD                       |                  | 0.940                    | 0.188         | 0.197     | <0.001                  |                 |
| HuGE Phenopedia           |                  | 0.979                    | 0.405         | 0.132     | <0.001                  |                 |
| Malacards                 |                  | 0.061                    | <0.001        | 0.217     | <0.001                  |                 |

NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) or through institutional hosting.
Enrichment of autism-associated genes in Tbr1 null transgenic mice

To showcase the broader applicability of MSET, we performed enrichment analysis for the full range of disease-associated gene lists in a set of expression data collected from murine T-box brain gene 1 (Tbr1) null developing neocortex [59]. The Tbr1 null animal was chosen because Tbr1 is a developmentally related transcription factor that binds, among other targets, the promoter of a gene called autism susceptibility candidate 2 (Auts2), named for its implication in autism susceptibility in the frontal cortex [59,60]. The Tbr1 null neocortex was observed to be enriched specifically for autism-associated gene sets (Figure 3), and not for any other mental health disorders included in our analysis (Figure 2). These findings suggest that, although inviable shortly after birth, the Tbr1 knockout animal may provide a valuable model for the study of autism-related biology. The Tbr1 null expression data also showed enrichment in two out of the four arthritis-associated gene sets. While this is not particularly strong enrichment, the observed variability could be due to broader physiological changes across numerous systems (possibly including the immune response) that must undoubtedly be affected by the fatal null mutation.

MSET enrichment analysis in expression data from methylphenidate treated mice

In addition to using MSET to analyze enrichment in expression results from animals that have undergone a natural change (mothers) and transgenic animals (Tbr1 null), we also tested its capabilities in a set of expression data from mice that were subjected to a pharmacological treatment. In the study, mice were treated with chronic (90 days) exposure to methylphenidate, commonly used to treat ADHD, and microarray analysis was performed on microdissected substantia nigra pars compacta (SNpc) [61]. In our enrichment analysis of these data, we observed...
a subtle degree of enrichment for autism-related gene sets (in three out of nine lists), but found that a consensus of enrichment was only detected for ADHD-related gene lists, and not for any other mental health disorder or arthritis (Figure 2). This shows that MSET can be effectively utilized with sensitivity in microarray data collected from a variety of different experimental protocols and treatments, providing a promising new strategy for exploring the genetics underlying mental health disorders from numerous, complementary angles.

Considerations and limitations of MSET analysis
MSET allows for powerful research possibilities, but there are numerous considerations that must be made regarding its appropriate application and the input parameters used. MSET utilizes a fairly simple gene randomization testing procedure to determine if members of a disease-associated gene set are overrepresented within significant microarray results compared to what would be expected by chance. This is in contrast to programs like GSEA, in which the coincident distribution of gene set members is characterized within a ranked list of microarray results using a running-sum statistic correlated to phenotype with individual sample expression values [9]. Accordingly, MSET calls for only one simple input file of summarized microarray gene results (in addition to disease-associated gene sets of interest), and does not require expression values, chip annotations, or phenotype/trait files. Some web applications exist for performing overrepresentation analysis (such as GOHyperGAll in Bioconductor, InnateDB, and GenMAPP-CS in the GO-Elite program), but they include problematic gene ID conversions, species limitations, a strict dependence on GO terms and existing ontologies, and inflexibility in generating custom gene sets. MSET

Figure 4 MSET evaluation of enrichment for autism and arthritis-associated genes within expression data from a murine arthritis model and postpartum LS. The left hand column of windows features the graphical output of MSET enrichment analyses for representative arthritis-associated gene lists (top three windows) and selected autism-associated gene lists (bottom two windows) within expression data from a mouse model of induced arthritis. The right hand column of windows shows the graphical assessment of enrichment for representative arthritis-associated genes within postpartum LS expression results. Y-axis represents the probability of X matches to database found in a randomly generated set of simulated results from the microarray background. The red arrow shows how many matches were found in the actual significant arthritis model expression changes and where that number falls on the probability density distribution, while the blue arrow represents matches in the actual significant postpartum LS expression results. The enrichment p-values are derived from the number of simulated results that contained at least as many matches to database as the actual results.
represents an advancement in versatility and ease of use over the existing landscape of tools for testing enrichment of independently curated disease-associated gene sets.

While MSET is theoretically capable of testing for enrichment of genes linked to functional pathways, using other, more full-featured programs for this purpose is recommended. It has been proposed that gene independence is a safe assumption for enrichment analysis [62]. Others have countered that gene-gene interaction can inflate p-values and generate false positives in functional enrichment. Due to the relatively simple nature of the randomization algorithm, independence is assumed in MSET analysis for disease enrichment. This is a safe assumption because disease gene sets are heterogeneous groups curated by phenotypic associations, rather than functional relatedness. However, it would be more conservative to use other programs that account for potential gene-gene interaction in functional enrichment analyses. GSEA, for instance, preserves gene-gene interaction by permuting labels of whole samples, rather than at the individual gene level [9].

Because enrichment analysis is highly sensitive to the input gene lists used [1], this will be a focus for much of the discussion regarding the performance of MSET. It can be seen in Figure 1 that the nine autism databases used in our analysis vary in both their identity and size. They also differ in the methods used to produce candidate autism gene lists; therefore, one should be aware that some databases may be more robustly assembled than others, and confidence in MSET results relies critically on confidence in upstream database quality. MSET’s reliability is bolstered by its capacity to test enrichment for multiple gene lists associated with the same disease; this feature minimizes the effects of weak associations on enrichment testing significance.

There is generally a balance between specificity of enrichment and the accuracy of its detection, which is related to gene list length. This is particularly relevant when extracting gene lists from general disease association databases (such as the DISEASES database, GAD, HuGE Phenopedia, and Malacards), which compile positive associations broadly across many diseases. Smaller gene lists may be more specific to their associated disease, but the MSET suffers from a decrease in the accuracy of hypothesis testing as the average number of matches found in simulated results becomes small. This can be seen in the probability density curves for database matches generated with the AutismKB and Malacards autism gene lists in Figure 1. Their “spiky” appearance reflects the highly discrete nature of distributions with a very small range. Consequently, chance variation in the number of matches in the microarray results being analyzed, even by a single gene, represents a disproportionately large jump in p-value from peak to peak. The smoother distributions generated from larger databases provide a much greater resolution for hypothesis testing; however, larger gene lists may be less biologically specific to the associated disease, and extremely large gene lists can result in false positive enrichment results. While there is assuredly some “true” degree of genetic overlap underlying various diseases, there is probably an additional level of similarity across seemingly unrelated conditions introduced artificially through the methodology of association studies and their aggregation. For example, one might expect genes featured in centrally important signaling pathways to show positive associations with many diseases and experimental conditions in microarray studies, leading to false positive results for enrichment of extremely large gene lists. Specificity can be further complicated by the detailed nature of disease association labels in comprehensive databases. For instance, the DISEASES database has separate gene lists for arthritis, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, septic arthritis, and more. The primary capacity of MSET to overcome these factors is rooted in its ability to be repeated modularly to generate a meta-analysis. This allows for isolated enrichment findings to be interpreted within the context of larger patterns. Also, because a deeper and more refined body of resources exists for autism genetics than for the other disorders featured in this study, we have relatively greater confidence in the downstream autism enrichment results. As ongoing research adds to our genetic understanding of various diseases, the MSET tool is in an ideal position to allow researchers to swiftly adapt and make use of updated knowledge bases in the future.

The tradeoff between specificity and accuracy also applies to the significant microarray results in which enrichment testing is performed. For postpartum LS expression data, we used an FDR-adjusted p-value of 0.25 as a significance threshold, which produced 809 genes from the microarray background. Researchers using other model organisms or biological systems may want to use different criteria for statistical significance. Other microarray studies may not yield a high number of significant gene changes by FDR-adjusted p-values. In these situations, a less stringent significance threshold may be applied to make use of a larger number of results, but the greater inclusivity and incidence of false discovery may render them somewhat less biologically meaningful. The subsequent enrichment analysis must therefore be taken with an accordingly critical interpretation.

MSET is designed to allow the user to conduct the most appropriate examination possible for enrichment of one or more disorders in a particular set of expression data. Due to the necessarily customizable nature of the input parameters that make for a quality assessment in one set of microarray results, it is difficult to objectively
compare enrichment across numerous expression results. In the current study, we have done so by standardizing both the number of significant expression results selected from the background and the databases used. It cannot be assumed that the 809 most significant genes from one study are as meaningful or specific as those from another study, but the comprehensive and identically repeated analysis performed here is a valuable preliminary comparison. Collectively, the analyses undertaken in the current study provide a promising indication that the MSET method can be a valuable and informative approach to large scale genetic questions.

Conclusions
In this article, we present the novel enrichment tool MSET as a lightweight alternative for performing enrichment analysis with custom-built, disease-associated gene lists. The value of MSET is twofold; firstly in its ease of use for researchers of any background due to its methodological simplicity and transparency, and secondly in the statistical hypothesis testing power offered by the ability to test enrichment within expression data modularly with numerous, independent gene-association databases. Using the MSET approach, we discovered that the maternal LS is highly enriched for autism-associated genes, as well as for genes linked to related mental health disorders, thus supporting a role for the maternal brain as a valuable translational model to the genetics of social and emotional disorders. By matching genes within significant expression results to autism genetic databases, we constructed a network of candidate genes that may regulate sociability in new mothers as well as in contexts of psychiatric illness. We further revealed that this network is primarily related to developmental processes, indicating that structural changes in LS likely underlie the modulation of social interaction and emotional reactivity in the postpartum state.

Availability and requirements
The Modular Single-set Enrichment Test (MSET) is available for download as Additional file 3, and is hosted online at https://sourceforge.net/projects/mset2013. It is written in R and requires the R command console to run, which can be downloaded from http://www.r-project.org/. It is licensed under the open source Apache 2.0 license. Refer to the MSET manual contained within the MSET folder for instructions on installation and use.

Additional files

Additional file 1: Table S1. Source information for the disease and autism association genetic databases used in this study.

Additional file 2: Table S2. Autism-associated genes found in significant (FDR-adjusted p < 0.25) postpartum LS expression results.

Additional file 3: MSET Folder containing MSET script and associated files.

Abbreviations
MSET: Multiple single-set enrichment test; LS: Lateral septum; AD/HD: Attention deficit hyperactivity disorder; BPD: Bipolar disorder; GSEA: Gene set enrichment analysis; DAVID: Database for annotation, visualization and integrated discovery; GO: Gene ontology; KEGG: Kyoto encyclopedia of genes and genomes; OMIM: Online mendelian inheritance in man; GAD: Genetic association database; AGD: Autism genetic database; GEO: Gene expression omnibus.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
BE, MS, TD, and SG conceived and developed the MSET script. BE carried out MSET validation on independent microarray data sets and performed MSET analysis on postpartum LS expression data. BE and SG drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was primarily funded by United States National Institutes of Health Grant R01 MH 085642 to S.G. Additional support was provided by the National Science Foundation Grant IOS-0921706 to S.G. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author details
1Department of Zoology, University of Wisconsin-Madison, Madison, Wisconsin, USA. 2Neuroscience Training Program, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Received: 30 July 2013 Accepted: 11 November 2013
Published: 19 November 2013

References
1. Da Huang W, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37(1):1–13.
2. Curtis RK, Oresic M, Vidal-Puig A: Pathways to the analysis of microarray data. Trends Biotechnol 2005, 23(8):429–435.
3. Da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4(1):44–57.
4. Ackermann M, Strimmer K: A general modular framework for gene set enrichment analysis. BMC Bioinformatics 2009, 10:47.
5. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3(Article3).
6. Kim SY, Volsky DJ: PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics 2005, 6:144.
7. Sheehan TP, Chambers RA, Russell DS: Regulation of affect by the lateral septum: implications for neuropsychiatry. Brain Res Brain Res Rev 2004, 46(1):71–117.
8. Olazabal DE, Pereira M, Agrati D, Ferreira A, Fleming AS, Gonzalez-Mariscal G, Levy F, Lucion AB, Morell J, Numan M, et al: Flexibility and adaptation of the neural substrate that supports maternal behavior in mammals. Neurosci Biobehav Rev 2013, 37(8):1857–1892.
9. Subramanian A, Tamayo P, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545–15550.
10. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Shakib S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34(2):267–273.
11. Eisinger BE, Zhao C, Dresenn TM, Saul MC, Gambinie SC: Large scale expression changes of genes related to neuronal signaling and...
Englund C, Fink A, Lau C, Pham D, Daza RA, Bulfone A, Kowalczyk T, Hevner RF: Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia, intermediate progenitor cells, and postmitotic neurons in developing neocortex. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 2005, 25(1):247–251.

Sadasivan S, Pond BB, Pani AK, Ou C, Jiao Y, Smeyne RJ: Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One 2012, 7(3):e33693.

Irizarry RA, Wang C, Zhou Y, Speed TP: Gene set enrichment analysis made simple. Stat Methods Med Res 2009, 18(6):565–575.

doi:10.1186/1471-2202-14-147
Cite this article as: Eisinger et al: Development of a versatile enrichment analysis tool reveals associations between the maternal brain and mental health disorders, including autism. BMC Neuroscience 2013 14:147.